- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07598058
PPDTM CorEvitasTM Chronic Hand Eczema (CHE) Drug Safety and Effectiveness Registry
5. juni 2026 opdateret af: CorEvitas
The design is a prospective, observational registry for subjects with CHE under the care of dermatology or other qualified healthcare provider.
Longitudinal data are collected from both subjects and their treating provider during routine clinical encounters using a structured and standardized data collection method
Studieoversigt
Status
Ikke rekrutterer endnu
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The objective of the registry is to create a cohort of CHE subjects to evaluate long-term real world safety and effectiveness of standard of care treatments for CHE.
Data collected through the registry may be used to address a range of research questions and use cases, including but not limited to: characterizing the natural history of the disease, evaluating the effectiveness and safety of commercially available medications for the treatment of CHE, providing information to support ongoing risk-benefit evaluation by drug manufacturers and regulators, and research related to drug utilization, disease burden, and unmet needs.
Further, data collected will inform clinical decision making by patients and treating providers.
Undersøgelsestype
Observationel
Tilmelding (Anslået)
2000
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiekontakt
- Navn: Cathy Cheney
- Telefonnummer: +1 508 408 5433
- E-mail: corevitasregistrytrials@corevitas.com
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
N/A
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
Subjects enrolled in this registry will be treated according to routine clinical care; treatments are prescribed at the provider's discretion and the decision to treat the subject with a drug is made prior to and independently of study participation.
The clinician will determine subject visit schedules according to routine practice, patient needs, and local standard of care (SoC)
Beskrivelse
Inclusion Criteria:
To be eligible to participate in this registry, an individual must meet all of the following criteria:
- Diagnosed with moderate-to-severe CHE by a dermatologist or other qualified healthcare provider at the time of enrollment and initiating an eligible medication.
- Is at least 18 years of age or older and has attained the legal age for consent to procedures involved in the research, under the applicable law of the jurisdiction in which the research is being conducted at the time of enrollment
- Is willing and able to consent to participation in the registry
- Is willing and able to complete registry-related forms electronically via personal devices.
- Is willing and able to provide the information (first name, last name, email address, language and primary time zone) required to create an account to allow you to complete registry forms via a personal device;
- Is willing and able to provide Personal Information (full legal name, sex, date of birth, home address zip or postal code and email address or phone number at a minimum) if required based on registry location and applicable laws and regulations.
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in the registry:
1) Is participating or planning to participate in a blinded clinical trial for a CHE drug
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
CHE Disease Epidemiology and presentation
Tidsramme: Every 6 months for 10 years
|
The major clinical outcome include an assessment of the epidemiology of CHE Disease; to better understand the presentation and natural history.
|
Every 6 months for 10 years
|
|
CHE Disease management, and outcomes
Tidsramme: Every 6 months for 10 years
|
The major clinical outcome include an assessment of the epidemiology of CHE Disease; to better understand the management and outcomes.
|
Every 6 months for 10 years
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Anslået)
29. maj 2026
Primær færdiggørelse (Anslået)
31. december 2099
Studieafslutning (Anslået)
31. december 2099
Datoer for studieregistrering
Først indsendt
13. maj 2026
Først indsendt, der opfyldte QC-kriterier
13. maj 2026
Først opslået (Faktiske)
20. maj 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
9. juni 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
5. juni 2026
Sidst verificeret
1. maj 2026
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CorEvitas-CHE-515
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Kronisk håndeksem
-
Ankara UniversityAfsluttetPsoriasis | Kontakt Dermatitis of HandKalkun
-
Jules Bordet InstituteMacopharma; Belgian Hematological SocietyRekrutteringRefractory Chronic Graft Versus Host Disease (cGVHD)Belgien
-
St Vincent's Hospital, SydneyUkendtHIV | HIV-associeret neurokognitiv lidelse (HAND)Australien
-
Steven BakerAfsluttetKontakt Dermatitis of HandForenede Stater
-
University of CalgaryCanadian Institutes of Health Research (CIHR); University of Alberta; Epidemiology...AfsluttetHIV-associeret neurokognitiv lidelse (HAND)Canada
-
University of UtahAfsluttetPhalanx of Supernumerary Digit of Hand
-
Duke UniversityNational Center for Advancing Translational Sciences (NCATS); Doris Duke... og andre samarbejdspartnereAfsluttet
-
Duke UniversityAmerican Academy of NeurologyAktiv, ikke rekrutterende
-
Berat GüngörIstanbul UniversityIkke rekrutterer endnuSeneskader | Zone 2 flexor sene Lacerations of the HandKalkun
-
Bahria UniversityIslamabad Medical and Dental CollegeAktiv, ikke rekrutterendeAlveolær knogletab Associated Chronic PeriodontitisPakistan
Kliniske forsøg med Observational (Non-Interventional) Registry
-
AstraZenecaAfsluttetBrystkræft | Onkologi | EpidemiologiAlgeriet
-
Methodist Health SystemAfsluttet